ArticleAnnals of surgical oncology2018
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 26 citations in OpenAlex.
- Preoperative total cholesterol and axillary lymph node burden in breast cancer: an exploratory analysis with a preliminary nomogram.Frontiers in surgery · 2026Article
- A Simplified Novel Algorithm to Predict the 21-Gene Recurrence Score.World journal of oncology · 2025Article
- OncoMark: a high-throughput neural multi-task learning framework for comprehensive cancer hallmark quantification.Communications biology · 2025Article
- Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience.Breast cancer research and treatment · 2025Article
- Anatomy Versus Biology: What Guides Chemotherapy Decisions in Older Patients With Breast Cancer?The Journal of surgical research · 2024Article
- YAP1 Expression in HR+HER2- Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation.Cancers · 2023Article
- Predicting Chemotherapy Benefit across Different Races in Early-Stage Breast Cancer Patients Using the Oncotype DX Score.Cancers · 2023Article
- Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?Annals of surgical oncology · 2023Article
- Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.Breast care (Basel, Switzerland) · 2022Article
- The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment.NPJ breast cancer · 2022Article
- Article
- Article
- Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.Breast cancer research and treatment · 2021Article
- Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.Geburtshilfe und Frauenheilkunde · 2020Article
- Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer.Cancer · 2020Article
- Article
- Impact of the 21-gene recurrence score assay on chemotherapy decision making and outcomes for breast cancer patients with four or more positive lymph nodes.Annals of translational medicine · 2019Article
- Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Clinical Impact of a Novel Model Predictive of Oncotype DX Recurrence Score in Breast Cancer.In vivo (Athens, Greece)Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
objectiveThe 21-gene Oncotype DX
methodsOverall, 610,350 tumor specimens examined by the Genomic Health laboratory from February 2004 to August 2017 were studied. Histology was classified centrally, while lymph node status was determined locally. RS distribution (low: < 18; intermediate: 18-30; high: ≥ 31) was compared by nodal status.
resultsEighty percent (n = 486,013) of patients were N0, 4% (n = 24,325) were N1mi, 9% (n = 56,100) were N+, and 7% (n = 43,912) had unknown nodal status. Mean RS result was 18, 16.7, 17.3 and 18.9 in the N0, N1mi, N+, and unknown groups, respectively. An RS ≥ 31 was seen in 10% of N0 patients, 7% of N1mi patients, and 8.0% of N+ patients. The likelihood of an RS ≥ 31 in N1mi and N+ patients varied with tumor histology, with only 2% of patients with classic infiltrating lobular cancer having an RS ≥ 31, versus 7-9% of those with ductal carcinoma.
conclusionsRS distribution among N0, N1mi, and N+ patients is similar, suggesting a spectrum of biology and potential chemotherapy benefit exists among node-negative and node-positive ER+/HER2- breast cancer patients. If RxPONDER does not show a chemotherapy benefit in N+ patients with a low RS result, our findings indicate that substantial numbers of patients could be spared the burden of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.